[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338917-105":59,"doc-detail-338917-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","evaluating-the-safety-profile-of-calcineurin-inhibitors-cancer-risk-in-patients-with-systemic-lupus-erythematosus-from-the-luna-registry-a-historical-cohort-study","Evaluating the safety profile of calcineurin inhibitors - cancer risk in patients with systemic lupus erythematosus from the LUNA registry - a historical cohort study","","Conflicting evidence surrounds cancer incidence in systemic lupus erythematosus (SLE) versus healthy individuals. This historical cohort study evaluates cancer incidence in SLE patients in the Lupus Registry of Nationwide Institutions (LUNA) and assesses whether calcineurin inhibitors (cyclosporine, tacrolimus) associate with cancer risk. Standardized incidence ratio estimates used Japan’s age-standardized population incidence. Analyses adjusted for key confounders including demographics, smoking, glucocorticoid exposure, treatment history, comorbidity, and disease damage.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluating-the-safety-profile-of-calcineurin-inhibitors-cancer-risk-in-patients-with-systemic-lupus-erythematosus-from-the-luna-registry-a-historical-cohort-study/338917/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluating-the-safety-profile-of-calcineurin-inhibitors-cancer-risk-in-patients-with-systemic-lupus-erythematosus-from-the-luna-registry-a-historical-cohort-study/338917.png","ImageObject",300,407,{"name":92,"@type":93},"Himbo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main purpose of this study?","Question",{"text":113,"@type":114},"To estimate cancer incidence among SLE patients in the LUNA registry and determine whether calcineurin inhibitor use is associated with cancer risk.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was cancer incidence quantified in the analysis?",{"text":118,"@type":114},"Cancer incidence was assessed using the standardized incidence ratio (SIR) based on Japan’s age-standardized cancer incidence rates.",{"name":120,"@type":111,"acceptedAnswer":121},"Did calcineurin inhibitor treatment significantly change cancer risk?",{"text":122,"@type":114},"No statistically significant cancer risks were found with CNI treatment history across multiple analytical approaches reported in the results.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},338917,1790386386,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197100911,"https://ap-avatar.wpscdn.com/avatar/a000239b6f1da00475?x-image-process=image/resize,m_fixed,w_180,h_180&k=1785132997149421697","Ichinose et al. Arthritis Research & Therapy (2024) 26:48 [https://doi.org/10.1186/s13075-024-03285-x](https://doi.org/10.1186/s13075-024-03285-x)  \nArthritis Research & Therapy  \n RESEARCH Open Access  \nEvaluating the safety profile of calcineurin  \ninhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry—a historical cohort study  \nKunihiro Ichinose1,2*, Shuntaro Sato3, Takashi Igawa 1, Momoko Okamoto1, AyukoTakatani1, Yushiro Endo 1, Sosuke Tsuji1, Toshimasa Shimizu1, Remi Sumiyoshi1, Tomohiro Koga1, Shin‑ya Kawashiri 1, Naoki Iwamoto 1, MamiTamai1, Hideki Nakamura4, Tomoki Origuchi5, Nobuyuki Yajima6, Ken‑Ei Sada7, Yoshia Miyawaki8, Ryusuke Yoshimi9, Yasuhiro Shimojima10, Shigeru Ohno11, Hiroshi Kajiyama 12, Shuzo Sato13,  \nMichio Fujiwara 14 and Atsushi Kawakami 1  \nAbstract  \nBackground Previous studies have shown conflicting evidence regarding the incidence of cancer in patients  \nwith systemic lupus erythematosus (SLE) compared with that in healthy individuals. Calcineurin inhibitors (CNIs) such as cyclosporine and tacrolimus have been widely used to treat SLE; however, their effects on cancer risk remain unclear. We aimed to investigate the incidence of cancer in patients with SLE and determine the potential association between CNI use and cancer risk.  \nMethods The standardized incidence ratio (SIR) of cancer among patients with lupus in the Lupus Registry of Nation‑ wide Institutions (LUNA) was calculated based on the age‑standardized incidence rate of cancer reported by Japan’s Ministry of Health, Labour and Welfare. We also examined the association between CNI exposure and cancer risk, while considering potential confounding factors. The analysis accounted for confounding variables such as age, sex, smoking history, maximum glucocorticoid dose, treatment history with cyclophosphamide, ongoing hydroxychlo‑ roquine, Systemic Lupus International Collaboration Clinics/American College of Rheumatology Damage Index (SDI) value (excluding cancer occurrence), comorbidity of diabetes mellitus, and smoking history.  \nResults The study included 704 patients with SLE (625 females; 88 . 8%) with a median age of 44 years [interquartile range (IQR) = 34–55] years. The median past maximum glucocorticoid dose was 40 mg/day [IQR = 30–60 mg/day], and the SDI at registration was 1 [IQR = 0–2] . Among the patients, 246 (35 . 1%) had smoking histories, and 38 (5 .4%) experienced cancer complications. Gynecological malignancies accounted for 63. 2% of all cancers. The SIR of cancer in the LUNA cohort was 1.08 (95% confidence interval [CI] = 0 .74–1.43) . No statistically significant risks of cancer were found in relation to CNI treatment history; the odds ratio using multiple logistic regression was 1.12 (95% CI = 0 .42– 3. 00), the risk ratio using standardization was 1.18 (95% CI = 0 .47–2. 16), and the risk ratio using inverse probability weighting was 1.8 (95% CI = 0 .41–4. 66) .  \n*Correspondence: Kunihiro Ichinose  \nkichinose@med. shimane‑[u.ac.jp](u.ac.jp)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://","cbCaibaUEnSOXqXj","https://ap.wps.com/l/cbCaibaUEnSOXqXj","pdf",821538,"English","# Abstract\n# Background\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What is the main purpose of this study?\",\"answer\":\"To estimate cancer incidence among SLE patients in the LUNA registry and determine whether calcineurin inhibitor use is associated with cancer risk.\"},{\"question\":\"How was cancer incidence quantified in the analysis?\",\"answer\":\"Cancer incidence was assessed using the standardized incidence ratio (SIR) based on Japan’s age-standardized cancer incidence rates.\"},{\"question\":\"Did calcineurin inhibitor treatment significantly change cancer risk?\",\"answer\":\"No statistically significant cancer risks were found with CNI treatment history across multiple analytical approaches reported in the results.\"}]","Evaluating the safety profile of calcineurin inhibitors - cancer risk in patients with systemic lupus erythematosus from the LUNA registry - a historical cohort study | PDF",1790026530,18,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a770c1bb809a4947620b2a26cf7f9860.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dfb14786605afe8bab6aed03b83f70b.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/686074f9be9d9dfddaf2ffd73725dbd6.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3028153d40b365e0b9eabce3e8b7a72.webp",980,1301]